AI assistant
Sending…
Tempest Therapeutics, Inc. — Director's Dealing 2014
Aug 28, 2014
34632_dirs_2014-08-28_02de5f84-b502-456d-8a80-12a2c6b09750.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: OvaScience, Inc. (OVAS)
CIK: 0001544227
Period of Report: 2014-08-26
Reporting Person: Stock Harald F. (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2014-08-26 | Common Stock | P | 580 | $12.9899 | Acquired | 12500 | Indirect |
Footnotes
F1: The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
F2: By SB Vermogensverwaltungs KG, a trust of which the reporting person is a majority shareholder and managing partner.
More from Tempest Therapeutics, Inc.
Proxy Solicitation & Information Statement
2026
Jun 8
Board/Management Information
2026
Jun 4
Regulatory Filings
2026
Jun 1
Board/Management Information
2026
May 29
Delisting Announcement
2026
May 22
Board/Management Information
2026
May 22
Interim / Quarterly Report
2026
May 14
Earnings Release
2026
May 14
Regulatory Filings
2026
May 6
Capital/Financing Update
2026
Apr 10